TEVA

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.07
Percentage change 0.41	%

Peers: JNJ ABBV AZN MRK GSK LLY PFE BMY NVS SNY

| Held by: IEFA EFA EFV IXUS PPH EIS SPDW IDEV IVLU DBEF

Index	-	P/E	-	EPS (ttm)	-1.45	Insider Own	0.02%	Shs Outstand	1.15B	Perf Week	-0.63%
Market Cap	18.74B	Forward P/E	5.93	EPS next Y	2.76	Insider Trans	-81.22%	Shs Float	1.15B	Perf Month	-4.68%
Income	-1639.00M	PEG	-	EPS next Q	0.49	Inst Own	58.66%	Short Float	2.43%	Perf Quarter	-0.93%
Sales	16.53B	P/S	1.13	EPS this Y	2.39%	Inst Trans	4.43%	Short Ratio	2.27	Perf Half Y	-8.37%
Book/sh	4.74	P/B	3.45	EPS next Y	8.14%	ROA	-3.96%	Short Interest	27.81M	Perf Year	22.80%
Cash/sh	2.88	P/C	5.68	EPS next 5Y	6.52%	ROE	-25.44%	52W Range	12.51 - 22.80	Perf YTD	-25.79%
Dividend Est.	-	P/FCF	9.19	EPS past 5Y	-9.62%	ROI	-7.56%	52W High	-28.26%	Beta	0.69
Dividend TTM	-	Quick Ratio	0.75	Sales past 5Y	-0.32%	Gross Margin	48.70%	52W Low	30.75%	ATR (14)	0.62
Dividend Ex-Date	Nov 27, 2017	Current Ratio	0.98	EPS Y/Y TTM	-206.85%	Oper. Margin	20.27%	RSI (14)	46.56	Volatility	3.32% 3.96%
Employees	36167	Debt/Eq	3.38	Sales Y/Y TTM	4.34%	Profit Margin	-9.91%	Recom	1.67	Target Price	24.43
Option/Short	Yes / Yes	LT Debt/Eq	3.03	EPS Q/Q	-147.24%	Payout	-	Rel Volume	0.44	Prev Close	16.29
Sales Surprise	2.00%	EPS Surprise	0.38%	Sales Q/Q	-6.32%	Earnings	Jan 29 BMO	Avg Volume	12.24M	Price	16.36
SMA20	1.01%	SMA50	-9.00%	SMA200	-8.28%	Trades		Volume	817,541	Change	0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-24	Upgrade	Argus	Hold → Buy	$20
Mar-08-24	Upgrade	JP Morgan	Underweight → Neutral	$14
Feb-12-24	Upgrade	Piper Sandler	Neutral → Overweight	$12 → $19
Jan-23-24	Upgrade	Jefferies	Hold → Buy	$10 → $14
Jan-03-24	Upgrade	Piper Sandler	Underweight → Neutral	$8 → $12
Dec-18-23	Initiated	HSBC Securities	Buy	$13
Nov-27-23	Upgrade	UBS	Neutral → Buy	$11 → $13
Jul-06-23	Upgrade	UBS	Sell → Neutral	$7 → $8
May-25-23	Initiated	Morgan Stanley	Equal-Weight	$10
May-18-23	Upgrade	Evercore ISI	In-line → Outperform
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $12
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight	$11 → $10
Nov-04-22	Downgrade	UBS	Neutral → Sell
Oct-21-22	Resumed	Jefferies	Buy	$10
Aug-05-22	Upgrade	BofA Securities	Neutral → Buy	$10 → $13
Jun-14-22	Resumed	UBS	Neutral	$10
May-17-22	Upgrade	BofA Securities	Underperform → Neutral	$9
May-04-22	Downgrade	Piper Sandler	Neutral → Underweight	$11 → $7
Apr-05-22	Upgrade	Barclays	Equal Weight → Overweight	$11 → $13
Mar-25-22	Upgrade	Bernstein	Mkt Perform → Outperform	$11

Show Previous Ratings

Mar-19-25 07:00AM	Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings (Fool)
Mar-18-25 03:22PM	Teva Pharmaceutical Stock Scores RS Rating Upgrade (Investor's Business Daily)
Mar-14-25 03:27AM	Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma (PR Newswire)
Mar-11-25 07:08AM	Teva debuts global campaign encouraging people to get outside (Retail Dive) +9.75%
Mar-03-25 04:30PM	Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March (GlobeNewswire)
05:04PM	Loading…
Mar-01-25 05:04PM	Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 (Insider Monkey)
02:52PM	Is Teva Pharmaceuticals Industries Limited (TEVA) the Best Weight Loss Drug Stock to Buy According to Analysts? (Insider Monkey)
Feb-28-25 02:11AM	Teva targets schizophrenia to build on innovative medicines growth (Pharma Voice)
Feb-27-25 08:34AM	Is Teva Pharmaceutical Industries Limited (TEVA) the Best Low Price Pharma Stock to Invest In Right Now? (Insider Monkey)
08:00AM	2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals (GlobeNewswire)
Feb-25-25 05:03PM	Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder (Business Wire)
04:00PM	Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder (GlobeNewswire)
02:06PM	Teva Pharmaceutical Industries Limited (TEVA): Among Bourgeon Capitals Top Stock Picks (Insider Monkey)
Feb-24-25 08:22AM	Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease (Benzinga)
06:38AM	Teva and Alvotech launch ustekinumab biosimilar injection in US (Pharmaceutical Technology)
06:19AM	Loading…
06:19AM	Sanofi, Teva add to case for new bowel disease drug (BioPharma Dive)
05:23AM	Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug (Clinical Trials Arena)
Feb-22-25 02:20AM	Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease (GlobeNewswire)
Feb-21-25 06:00AM	Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S. (GlobeNewswire)
Feb-20-25 05:06AM	Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist (Motley Fool)
Feb-19-25 08:28AM	Is Teva Pharmaceutical (TEVA) Trading at a Discount? (Insider Monkey)
Feb-18-25 04:30PM	Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) (GlobeNewswire)
11:27AM	FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea (Investopedia)
06:00AM	Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept) (GlobeNewswire)
Feb-14-25 06:32PM	Stanley Druckenmiller's Strategic Moves: A Closer Look at Teva Pharmaceutical Industries Ltd (GuruFocus.com)
Feb-10-25 12:33PM	Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' (Benzinga)
06:45AM	Axsome secures top drugs future with Teva patent settlement (BioPharma Dive)
Jan-31-25 08:00AM	This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry (Investor's Business Daily)
02:14AM	Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Highlights: Strong Revenue ... (GuruFocus.com)
Jan-30-25 07:05AM	Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday? (Insider Monkey)
03:37PM	Loading…
Jan-29-25 03:37PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research) -13.89%
02:26PM	Why Teva Pharmaceutical Stock Is Sinking Today (Motley Fool)
02:15PM	Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript (Motley Fool)
01:18PM	Teva Stock Dives 14%. Why Its CEO Says It's A Victim. (Investor's Business Daily)
01:18PM	Teva Stock Dives 14%. 'We're Victims Of Our Own Success,' Says CEO. (Investor's Business Daily)
12:43PM	Trump Media's Truth.Fi, T-Mobile, Teva: Market Minute (Yahoo Finance Video)
11:39AM	VF Corp, Corning, Teva: Trending stocks (Yahoo Finance Video)
09:32AM	Teva Pharmaceutical Posts Lower Revenue. Stock Slips. (Investor's Business Daily)
09:30AM	Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:00AM	Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth (GlobeNewswire)
Jan-27-25 06:00AM	Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi and Simponi Aria (golimumab) (GlobeNewswire)
Jan-23-25 07:44AM	FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases (Pharmaceutical Technology)
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Jan-17-25 09:46AM	Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations (Yahoo Finance)
Jan-13-25 11:55AM	How Teva Pharmaceuticals is thinking about Trump's return: CEO (Yahoo Finance Video)
01:00AM	Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea (aflibercept) in major parts of Europe and in Israel (GlobeNewswire)
Jan-10-25 08:30AM	Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI (eculizumab-aagh) in the United States (GlobeNewswire)
Jan-09-25 12:31PM	Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical (Benzinga)
Jan-08-25 04:10PM	IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva (Investor's Business Daily)
Jan-03-25 10:47AM	Why Teva Pharmaceuticals Industries Ltd. (TEVA) Crashed Yesterday (Insider Monkey)
Dec-28-24 09:27AM	Teva Pharmaceutical Industries Ltd (TEVA) Ends Trading Week Defying Market Bloodbath (Insider Monkey)
Dec-24-24 04:51AM	Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025 (Motley Fool)
04:05AM	Why Teva Pharmaceuticals Industries (TEVA) Skyrocketed? (Insider Monkey)
Dec-23-24 04:30PM	Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-24 07:58AM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
Dec-20-24 04:30PM	Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 (GlobeNewswire)
04:51AM	My Top 10 Portfolio Holdings for 2025 (Motley Fool)
Dec-19-24 07:45AM	Teva price target raised to $28 from $26 at UBS (TipRanks)
Dec-18-24 02:50PM	Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments? (Insider Monkey)
07:08AM	Fed decision looms, Nvidia looks to rebound: Yahoo Finance (Yahoo Finance Video)
06:39AM	Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength? (Zacks)
05:26AM	Sanofi and Tevas duvakitug meets primary endpoints in Phase IIb trial (Clinical Trials Arena)
Dec-17-24 09:47PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research) +26.47%
04:36PM	Teva and Sanofi jump on experimental bowel disease drug success (Yahoo Finance Video)
04:10PM	Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug (Investor's Business Daily)
01:20PM	Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's (Investopedia)
12:00PM	Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations (GuruFocus.com)
11:55AM	Teva Catapults 22%, Hitting A Five-Year High, After Scoring A Win With Sanofi-Tied Drug (Investor's Business Daily)
11:51AM	Teva, Cloudflare, Sanofi: Trending Tickers (Yahoo Finance Video)
11:51AM	Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment (The Wall Street Journal)
10:37AM	Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug (Investor's Business Daily)
09:17AM	Teva Stock Soars on Early Bowel Disease Drug Data (Barrons.com)
09:17AM	Teva Shares Soar on Early Bowel Disease Drug Data (Barrons.com)
09:16AM	Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? (Benzinga)
07:30AM	Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease (GlobeNewswire)
Dec-11-24 08:00AM	Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients (GlobeNewswire)
Dec-05-24 06:00PM	Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan (GlobeNewswire)
05:13AM	Teva reports positive outcomes from episodic migraine trial in young patients (Clinical Trials Arena)
Dec-04-24 02:00AM	Teva Presents Positive Efficacy and Safety Data of AJOVY (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial (GlobeNewswire)
Nov-25-24 06:00PM	Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-21-24 02:47AM	Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25 (Insider Monkey)
Nov-15-24 09:09AM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
Nov-08-24 04:30PM	Teva to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
09:40AM	Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now? (Zacks)
Nov-07-24 02:06AM	Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ... (GuruFocus.com)
Nov-06-24 04:06PM	'This Is A New Teva,' Says CEO. But Investors Don't Seem To Believe. (Investor's Business Daily) -7.14%
02:41PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
02:08PM	Teva Retreats, Sacrificing A Breakout, Despite Its Third-Quarter Beat And Raise (Investor's Business Daily)
11:30AM	Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript (Motley Fool)
10:08AM	Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge (GuruFocus.com)
09:30AM	Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:57AM	Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report (Investor's Business Daily)
07:00AM	Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS (GlobeNewswire)
Nov-04-24 12:00PM	Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Nov-01-24 03:05PM	Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition (GlobeNewswire)
03:00PM	Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY (risperidone) (GlobeNewswire)
09:15AM	Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
06:40AM	EC fines Teva $502m over multiple sclerosis treatment Copaxone practices (Pharmaceutical Technology)
Oct-31-24 02:49PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
09:26AM	Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns (The Wall Street Journal)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Daniell Richard	Exec. VP, European Commercial	Mar 05 '25	Sale	15.91	70,961	1,128,642	48,384	Mar 07 04:05 PM
Hughes Eric A	See "Remarks"	Mar 04 '25	Sale	15.73	15,174	238,757	8,077	Mar 06 04:11 PM
Hughes Eric A	See "Remarks"	Mar 05 '25	Sale	15.91	8,077	128,531	0	Mar 06 04:11 PM
Daniell Richard	Exec. VP, European Commercial	Mar 04 '25	Sale	15.73	91,608	1,441,415	7,108	Mar 06 04:06 PM
Daniell Richard	Exec. VP, European Commercial	Mar 05 '25	Sale	15.91	48,764	775,991	0	Mar 06 04:06 PM
Francis Richard D	President and CEO	Mar 04 '25	Sale	15.73	15,514	244,107	280,042	Mar 06 04:03 PM
Francis Richard D	President and CEO	Mar 05 '25	Sale	15.91	8,259	131,427	271,783	Mar 06 04:03 PM
Daniell Richard	Officer	Mar 05 '25	Proposed Sale	15.83	70,961	1,123,585		Mar 05 04:29 PM
Daniell Richard	Exec. VP, European Commercial	Mar 03 '25	Sale	16.19	49,314	798,172	12,936	Mar 05 04:12 PM
Daniell Richard	Exec. VP, European Commercial	Mar 04 '25	Sale	15.56	12,936	201,253	0	Mar 05 04:12 PM
Hughes Eric A	See "Remarks"	Mar 03 '25	Sale	16.19	19,726	319,275	5,174	Mar 05 04:08 PM
Hughes Eric A	See "Remarks"	Mar 04 '25	Sale	15.56	5,174	80,495	0	Mar 05 04:08 PM
Francis Richard D	President and CEO	Mar 03 '25	Sale	16.19	24,892	402,889	251,783	Mar 05 04:04 PM
Francis Richard D	President and CEO	Mar 04 '25	Sale	15.56	6,450	100,347	245,333	Mar 05 04:04 PM
Fox Christine	Officer	Mar 04 '25	Proposed Sale	16.00	6,181	98,896		Mar 04 07:02 PM
McAvoy David R.	Officer	Mar 04 '25	Proposed Sale	16.00	4,827	77,232		Mar 04 06:57 PM
Hughes Eric A	Officer	Mar 04 '25	Proposed Sale	16.00	23,251	372,016		Mar 04 06:44 PM
Daniell Richard	Officer	Mar 04 '25	Proposed Sale	16.00	86,400	1,382,400		Mar 04 06:37 PM
Francis Richard D	Officer	Mar 04 '25	Proposed Sale	16.00	23,773	380,368		Mar 04 06:30 PM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Feb 28 '25	Sale	16.21	55,750	903,462	147,941	Mar 04 04:02 PM
Francis Richard D	Officer	Mar 03 '25	Proposed Sale	16.46	31,342	515,889		Mar 03 01:14 PM
Hughes Eric A	Officer	Mar 03 '25	Proposed Sale	16.46	24,900	409,854		Mar 03 01:07 PM
Daniell Richard	Officer	Mar 03 '25	Proposed Sale	16.46	62,250	1,024,635		Mar 03 12:59 PM
Kalif Eliyahu Sharon	Officer	Feb 28 '25	Proposed Sale	16.21	55,750	903,463		Feb 28 11:52 AM
Francis Richard D	President and CEO	Feb 18 '25	Sale	16.95	75,506	1,279,661	209,444	Feb 19 04:03 PM
Francis Richard D	Officer	Feb 18 '25	Proposed Sale	16.95	75,506	1,279,661		Feb 18 12:38 PM
Sabag Mark	See "Remarks"	Feb 12 '25	Sale	16.25	177,626	2,886,565	204,964	Feb 14 04:03 PM
Sabag Mark	Officer	Feb 12 '25	Proposed Sale	16.25	177,626	2,886,555		Feb 13 08:06 AM
MIGNONE ROBERTO	Director	Dec 20 '24	Sale	22.01	286,000	6,294,031	695,000	Dec 26 04:02 PM
Bridger Management, LLC (1)	Shareholder	Dec 20 '24	Proposed Sale	21.31	286,000	6,094,660		Dec 20 07:03 PM
Fox Christine	EVP, Head of U.S. Commercial	Nov 20 '24	Sale	16.87	19,388	327,085	44,104	Nov 21 04:04 PM
Fox Christine	Officer	Nov 20 '24	Proposed Sale	16.87	19,388	327,085		Nov 20 11:39 AM
Daniell Richard	Exec. VP, European Commercial	Aug 12 '24	Sale	17.30	98,943	1,711,447	0	Aug 13 04:09 PM
Grant Angus	EVP, Business Development	Aug 09 '24	Sale	17.28	4,065	70,243	8,848	Aug 13 04:06 PM
Hughes Eric A	See "Remarks"	Aug 09 '24	Sale	17.38	45,060	782,972	0	Aug 13 04:02 PM
Daniell Richard	Officer	Aug 12 '24	Proposed Sale	17.30	98,943	1,711,444		Aug 12 04:09 PM
Hughes Eric A	Officer	Aug 09 '24	Proposed Sale	17.38	45,060	782,974		Aug 12 03:59 PM
Grant Angus	Officer	Aug 09 '24	Proposed Sale	17.28	4,065	70,243		Aug 09 03:59 PM
Hughes Eric A	See "Remarks"	Aug 01 '24	Sale	17.25	24,537	423,280	45,060	Aug 05 07:35 AM
Hughes Eric A	Officer	Aug 01 '24	Proposed Sale	17.25	24,537	423,281		Aug 01 04:00 PM
MIGNONE ROBERTO	Director	Jun 18 '24	Sale	17.03	519,000	8,838,570	981,000	Jun 21 04:05 PM
Weiss Amir	Chief Accounting Officer	May 15 '24	Sale	16.80	15,500	260,417	17,814	May 17 07:41 AM
Weiss Amir	Chief Accounting Officer	May 16 '24	Sale	16.65	12,635	210,377	5,179	May 17 07:41 AM
Conway Vikki L	See "Remarks"	May 13 '24	Sale	16.74	15,219	254,807	0	May 15 08:36 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Teva- Pharmaceutical Industries Ltd. ADR

Upgrade your FINVIZ experience